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Photodynamic therapy (PDT) with Photofrin has now been
approved by regulatory authorities in several countries and an
increasing number of patients are being treated. Nevertheless, the
need for new clinical photosensitizers with improved purity,
tumour selectivity, light absorption profile, photophysical proper-
ties and tissue clearance has been recognized (Bellnier and
Henderson, 1992; Dougherty, 1993). Phthalocyanines have the
potential to fulfil many of these criteria (Ben Hur, 1992; Fingar et
al, 1993; Griffiths et al, 1994) but, although many potential candi-
dates have been studied experimentally (Spikes, 1986; Ben Hur et
al, 1987), there has been little clinical application and that appears
to have been restricted largely to the use of aluminium sulphonated
phthalocyanine in Russia (Stranadko et al, 1996).
We have developed a series of novel photosensitizers based on
zinc(II) phthalocyanine, rendered water-soluble by appropriate
substitution at the periphery of the molecule (Cruse-Sawyer et al,
1998). Three such sensitizers are of particular interest in mecha-
nistic terms, since they contain negatively charged, positively
charged and neutral peripheral groups respectively (Figure 1). The
substitution does not significantly alter the photophysical properties
of the molecules in terms of absorption spectra and singlet oxygen
generation and the compounds therefore offer a means of compara-
tively assessing the effects of charge on such parameters as uptake
into tumours and other tissues, pharmacokinetics, sub-tumoural and
sub-cellular distribution and PDT efficacy.
One of the complicating features of PDT is the large number of
treatment parameters which have to be set compared with other
modalities. These include choice of drug, drug dose, light dose,
light dose rate, drug-time interval and mode of light delivery (e.g.
interstitial versus surface illumination). Optimization of these
parameters for particular indications is difficult and is associated
with variability in outcome. It would be extremely valuable if a
physical technique could be used to predict PDT efficacy at the
time of treatment, when appropriate adjustment to at least some 
of these treatment parameters would be possible. In principle,
magnetic resonance spectroscopy (MRS) offers this possibility
through measurement of phosphate metabolism during and imme-
diately after light irradiation. Work in several laboratories has
shown that 31P MRS does indeed reveal early changes in phos-
phate metabolism either during or following PDT (Ceckler et al,
1986; Chopp et al, 1987; Hilf et al, 1987; Mattiello et al, 1990;
Chapman et al, 1991; Bremner et al, 1994).
The main aims of the current paper are twofold. First, we have
carried out a MRS study in a mouse model, using the three novel
cationic, anionic and neutral zinc phthalocyanines developed at
Leeds, to determine if measurements made at the time of PDT
treatment can be predictive of ultimate PDT efficacy. Secondly, we
31P magnetic resonance spectroscopy as a predictor of
efficacy in photodynamic therapy using differently
charged zinc phthalocyanines
JCM Bremner1, SR Wood2,4, JK Bradley1, J Griffiths3,4, GE Adams1 and SB Brown2,4
1MRC Radiobiology Unit, Chilton, Didcot OX11 0RD, UK; 2School of Biochemistry and Molecular Biology, 3Department of Colour Chemistry and Dyeing and
4Centre for Photobiology and Photodynamic Therapy, University of Leeds, Leeds LS2 9JT, UK
Summary Photodynamic therapy (PDT) is a developing approach to the treatment of solid tumours which requires the combined action of light
and a photosensitizing drug in the presence of adequate levels of molecular oxygen. We have developed a novel series of photosensitizers
based on zinc phthalocyanine which are water-soluble and contain neutral (TDEPC), positive (PPC) and negative (TCPC) side-chains. The
PDT effects of these sensitizers have been studied in a mouse model bearing the RIF-1 murine fibrosarcoma line studying tumour regrowth
delay, phosphate metabolism by magnetic resonance spectroscopy (MRS) and blood flow, using D2O uptake and MRS. The two main aims of
the study were to determine if MRS measurements made at the time of PDT treatment could potentially be predictive of ultimate PDT efficacy
and to assess the effects of sensitizer charge on PDT in this model. It was clearly demonstrated that there is a relationship between MRS
measurements during and immediately following PDT and the ultimate effect on the tumour. For all three drugs, tumour regrowth delay was
greater with a 1-h time interval between drug and light administration than with a 24-h interval. In both cases, the order of tumour regrowth
delay was PPC > TDEPC = TCPC (though the data at 24 h were not statistically significant). Correspondingly, there were greater effects on
phosphate metabolism (measured at the time of PDT or soon after) for the 1-h than for the 24-h time interval. Again effects were greatest with
the cationic PPC, with the sequence being PPC > TDEPC > TCPC. A parallel sequence was observed for the blood flow effects,
demonstrating that reduction in blood flow is an important factor in PDT with these sensitizers. © 1999 Cancer Research Campaign
Keywords: photodynamic therapy; magnetic resonance; phthalocyanines
616
British Journal of Cancer (1999) 81(4), 616–621
© 1999 Cancer Research Campaign
Article no. bjoc.1999.0738
Received 26 November 1998
Revised 22 April 1999
Accepted 26 April 1999
Correspondence to: SB Brown; School of Biochemistry and Molecular
Biology, University of Leeds, Leeds LS2 9JT, UK
This paper was prepared with the full participation of Professor GE Adams, before
his death on 6 June 1998.have used the same three sensitizers to assess the effects of charge
on PDT efficacy and whether any MRS correlation is itself depen-
dent on the sensitizer charge. As a secondary aim, we have taken
advantage of the ability of MRS to measure blood flow immedi-
ately following PDT under the same conditions used in the main
study, to assess whether reduction in blood flow represents an
important mechanism of tumour damage using these sensitizers.
MATERIALS AND METHODS
Photosensitizers
Three phthalocyanines differing in the structure of their
constituent side-chains and overall net charge (Figure 1) were
synthesized in the Department of Colour Chemistry, University of
Leeds. Tetradihydroxyethylsulphonamide zinc phthalocyanine
(TDEPC), Pyridinium methyl zinc phthalocyanine (PPC) and
tetracarboxy zinc phthalocyanine (TCPC) have neutral, positive
and negative charges respectively and all are water-soluble. The
preparation and characterization of these compounds have been
described previously (Griffiths et al, 1997).
Each compound was dissolved in isotonic saline to a concentra-
tion of 2 mg ml–1 and administered intravenously (i.v.) at a dose of
10 mg kg–1.
Tumour model
The RIF-1 murine sarcoma line was maintained as described
previously (Twentyman et al, 1980; Stratford et al, 1988).
Approximately 2 ´ 105 cells suspended in 0.05 ml phosphate-
buffered saline (PBS) were implanted intradermally (i.d.) into the
mid-dorsal pelvic region of 8- to 10-week-old male C3H/He mice
(category IV).
Tumour regrowth delay
The tumours were measured in three orthogonal directions (a, b
and c) using graduated vernier callipers. Their volumes (V) were
calculated using the formula V = abc ´p /6. The mice were used
for treatment when their tumours had reached a volume of 80–
160 mm3. Following treatment, the tumours were measured three
times per week and the time taken for each tumour within a group
to reach four times its volume at the start of treatment was cal-
culated. Six animals per group were used and the mean (± s.e.m.)
of the regrowth times for each treated group was calculated. From
these data the growth delay was calculated as Texp–Tcon, where
Tcon and Texp are the mean times taken to reach four 
times volume for the control and relevant experimental groups
respectively.
Anaesthetic
For both the growth delay and MRS studies the mice were
anaesthetized using a 1:1:2 mixture of Hypnorm/Hypnovel/water
20 min prior to giving the light dose.
Light source
A Spectra Physics 2016-6W argon ion-pumped dye laser was used
to generate light at a given wavelength by tuning the birefringent
filter. The light was then directed down a fibreoptic cable which
ran directly from the laser facility to the magnetic resonance
building. A 200-mm diameter core hard clad silica (HCS) single
fibre with a ruggedized external sheathing was used. This was
coupled to the laser light using a multimode fibre coupler
(Newport Corporation). The end of this fibre (230 mm outer diam-
eter) was cleaved and inserted interstitially into the centre of the
tumour, parallel to the body of the mouse. Only one fibre was
required for each tumour.
The power density of the light, measured before insertion, was
100 mW cm–2 and the duration of the exposure was 500 s to give a
total light dose of 50 J cm–2. The wavelengths of light used to acti-
vate TDEPC, PPC and TCPC were 680, 680 and 692 nm respec-
tively (Griffiths et al, 1994) (Figure 2). The time interval between
giving the photosensitizer and the light dose was either 1 or 24 h.
Magnetic resonance spectroscopy
All experiments were performed in a 4.7 Tesla superconducting
magnet with a 30 cm horizontal bore (Oxford Instruments)
connected to a SISCO 200 spectrometer (Varian Associates)
(Bremner et al, 1994). The body temperature of the anaesthetized
mice in the magnet was maintained at 34–35°C by a device for
circulating hot water.
Phosphorus metabolism
A two-turn, 7-mm diameter surface coil that fitted neatly over the
tumour was used both as transmitter and receiver. Each spectrum
accumulated consisted of 256 acquisitions collected in 512 s, using
a 2 s repetition rate, 0.1 s acquisition time and a spectral width of
5000 Hz.
Prior to placement in the magnet, the optical fibre was inserted
into the tumour of the anaesthetized mouse, and the mouse was
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Table 1 Regrowth delay (± s.e.m.) induced in RIF-1 tumours by the different
PCs following a 50 J cm–2 dose of light when the drug–light time interval (TL)
was either 1 or 24 h
PC
Regrowth delay (days)
(10 mg kg–1) TL = 1 h TL = 24 h
PPC 12.5 ± 1.8 6.1 ± 1.1
TCPC 8.2 ± 1.7 4.6 ± 1.4
TDEPc 7.8 ± 0.9 3.0 ± 1.3
All mice were anaesthetized and six animals were used per group. The
tumour growth delays were calculated as described in Materials and
Methods.
Figure 1 The chemical structure of the phthalocyanines PPC, TCPC and
TDEPC618 JCM Bremner et al
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then positioned in the centre of the magnet. For each mouse a
control spectrum was collected and then, without moving the
mouse, the light irradiation was given (Bremner et al, 1994). In
this way it was possible to store the spectrum once halfway
through the irradiation time (i.e. after 128 scans – 4 min) and again
at the end (after 256 scans). Spectra were then collected immedi-
ately after irradiation and subsequently at 10-min intervals for 1 h.
At 24 h following treatment the unanaesthetized mice were lightly
restrained in plastic jigs and replaced in the centre of the magnet
where a final spectrum was obtained.
The spectra were analysed as described previously (Bremner et
al, 1994) and the ratio of the area under the inorganic phosphate
(Pi) peak to the total area under all the peaks (Pi/total) was used to
indicate the changes occurring in the spectra and hence in phos-
phate metabolism. As cell mitochondrial function is damaged (due
to PDT, for example) the Pi/total P ratio increases and hence this
ratio can be used as an early measure of cell damage. As we have
previously reported (Bremner et al, 1991) when the Pi/total ratio is
above approximately 0.4 it is difficult to distinguish the level of
ATP from the background noise. Therefore any increase in the
ratio above this value is likely to be due to a change in the Pi:phos-
phomonoester ratio and not to further changes in ATP levels. The
time points on the graphs correspond to the mid-points of the
collection times.
For statistical analysis, a Student’s t-test (P < 0.05) was used to
obtain a comparison of Pi/total ratios for the treated and control
groups.
Deuterium (D2O) uptake measurements
A five-turn solenoid surface coil of 1-cm diameter was used
(Bradley et al, 1994). Each spectrum was acquired in 15 s and
contained averaged data from 75 scans at a repetition time of 0.2 s,
0.1-s acquisition time and a spectral width of 2500 Hz. For each
uptake measurement an array of 70 spectra were obtained in 
20 min. Relative HDO concentrations were estimated from the
height of the HDO peaks.
A cannula (Jelco, 24 gauge) rinsed with heparin and connected
to silicone tubing was inserted into the tail vein of the mouse. The
tubing was filled with D2O–saline (0.9% w/v sodium chloride) and
connected to a 1-ml syringe situated outside the magnet bore. In
the mouse, D2O becomes a tracer molecule (HDO) through the
rapid exchange of protons. In order to obtain a background level of
HDO, five complete spectra were obtained before injecting 70 ml
of D2O during the 6th scan.
A control HDO uptake rate was measured immediately before
light irradiation for each anaesthetized mouse and then further
measurements were made 5, 30, 60 min and 24 h after treatment.
The analysis of the D2O data has been described in detail previ-
ously (Bradley et al, 1994; Bremner et al, 1994). The tumour blood
flow (TBF) following treatment is calculated as a value relative to
its own control. The time points on the graphs (Figure 3) corre-
spond to the mid-points of the collection times.
RESULTS
Photodynamic therapy
The growth time for the RIF-1 tumours in the control (no drug and
no light) animals was 7.7 ± 0.1 days to reach four times original
tumour volume. This represents the Tcon parameter defined in the
Materials and Methods section. Under the PDT conditions chosen,
a significant effect on tumour regrowth for the RIF-1 tumours was
found for each of the sensitizers (P < 0.05), demonstrating that
each sensitizer was effective in tumour control. Values for the
regrowth delay, as defined in Materials and Methods, with each of
the phthalocyanines, are shown in Table 1. With drug alone or with
light alone there was no significant regrowth delay.
Table 1 clearly shows that when the drug–light interval was 1 h,
regrowth delay was greater than when the interval was 24 h for
each of the sensitizers, presumably due to clearance of the drug
from the tumours. It is also apparent that there are differences in
efficacy between the sensitizers. At the 1-h drug–light time
interval, the order of effectiveness was PPC > TDEPC = TCPC.
Analysis of variance (ANOVA) demonstrated that PPC was signi-
ficantly different to TDEPC (P < 0.05) but there was no significant
difference between TDEPC and TCPC. At the 24-h time interval,
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Figure 2 PDT-induced changes in the Pi/total ratio during and after a light
dose of 50 J cm–2 with either TDEPC (A), PPC (B) or TCPC (C). The drugs
were given i.v. at a dose of 10 mg kg–1. Results are shown for TL values 
of 1 (l) or 24 h (l l). The vertical hatched line indicates the duration of light
treatment (500 s). The horizontal hatched lines shows the Pi/total ratios
(mean ± s.e.m.) observed in untreated control tumours. The dotted line in A
shows the changes in the ratio occurring when tumour blood flow is occluded
using mechanical clamps31P magnetic resonance spectroscopy as a predictor of efficacy 619
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again the order of effectiveness appeared to be PPC > TDEPC =
TCPC, though ANOVA demonstrated no significant differences at
this time point.
It should be emphasized that, in this study, the aim was not to
use conditions which produced maximum PDT effects, but to use
conditions which produced different PDT effects, both for the
different sensitizers and for the different drug–light intervals, so
that the variation in efficacy could be used to assess correlation
with the MRS data. In this respect, therefore, the conditions have
clearly proved appropriate.
31P magnetic resonance spectroscopy
Figure 2 shows the changes induced in Pi/total ratios obtained
from the phosphorus spectra following a PDT dose of 50 J cm–2
when the three PCs were administered either 1 or 24 h before the
light. It is clear that, for each sensitizer at the 1-h drug–light time
interval, there were substantial initial effects on the phosphorus
spectrum, in agreement with previous studies with other sensi-
tizers. This result shows for the first time that, with these sensi-
tizers, there are rapid changes in phosphorus metabolism during or
immediately after PDT and that these changes may be assessed in
relation to their use in predicting ultimate PDT outcome. However,
when the drug–light time interval was 24 h, the effects were much
less. They were smaller for PPC but, for TDEPC and TCPC, they
were not distinguishable from controls.
For the 1-h drug–light time interval, a more detailed analysis
shows that, over the first hour following PDT, the effect is in the
sequence PPC > TDEPC > TCPC, though distinction between
PPC and TDEPC at short times would be difficult. For the 24-h
drug–light time interval, the corresponding order is PPC > TDEPC
= TCPC. Under all conditions where an effect relative to control
was observed, the Pi/total ratio increased rapidly initially, then
plateaued after 10–30 min up until at least 60–70 min, except in
the case of TCPC where the already small effect decreased further
after about 50 min. It was not possible to carry out a series of
longer time measurements, but it was possible to carry out a single
measurement at 24 h in each case. Interestingly, without excep-
tion, these values show a significant increase over the plateau
level.
For one sensitizer, TDEPC, the effect on the Pi/total ratio of
occlusion of the blood supply by a metal clamp was studied.
Results are shown by the dotted line in Figure 2A for a 1-h
drug–light interval. Although this study used only one animal per
time point, the trend suggests that the initial effects of PDT on
phosphorus metabolism appear to be substantially smaller with a
clamped vessel.
Blood flow
Figure 3 shows measurements of blood flow in terms of the rela-
tive HDO uptake rate for all three sensitizers, as described in
Materials and Methods. When the drug–light interval was 1 h,
PDT treatment with both TDEPC and PPC (Figure 3 A, B)
reduced the tumour blood flow by 80 and 95% of control values
respectively, within the first 10 min post-treatment. The PDT
effect on blood flow with TCPC (Figure 3C) showed only about a
40% decrease, i.e. the sequence was PPC > TDEPC > TCPC. In all
three cases, the initial reduction in blood flow was maintained for
at least the first hour and rose only slightly after 24 h.
When the drug–light interval was 24 h, the tumour blood flow
remained within the range expected for untreated tumours for up
to 24 h following light treatment with either TDEPC or TCPC.
However, with PPC, the tumour blood flow fell by approximately
60% of the control level within 10 min post-treatment and this
reduction was maintained for up to 24 h, i.e. the sequence was
PPC > TDEPC = TCPC.
DISCUSSION
Correlation between PDT efficacy and MRS
measurements
One of the two main objectives addressed by the present paper is the
question of whether differences in the PDT efficacy, measured many
days after treatment and representing both variation in sensitizer and
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Figure 3 The relative changes in blood flow as measured by deuterium
uptake against time after a PDT light dose of 50 J cm–2 with either TDEPC
(A), PPC (B) or TCPC (C). Results are shown for TL values of 1 (l) or 24 h
(l l). The change in uptake rate of HDO is plotted as a percentage of the
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variation in drug–light interval, might be reflected in the MRS
measurements taken during and immediately after PDT. In broad
terms, it is clear that there is indeed such correlation. Considering
variation in sensitizer, at the 1-h interval, PPC was the most effective
in PDT and also gave the greatest effect on phosphate metabolism.
Comparing PPC itself at the two time intervals also shows broad
correlation between growth delay and initial change in phosphate
metabolism. However, these correlations cannot be pressed too far
from the present data since, at the 1-h interval, although TDEPC
showed an apparently greater phosphate metabolism effect than
TCPC, their PDT efficacies were not distinguishable. Moreover, at
the longer time interval, there were no significant differences in
phosphate metabolism above control values, yet both sensitizers did
give a definite PDT effect.
The present data suggest, therefore, that MRS measurements
certainly have the potential to be predictive of ultimate PDT effect
and, even in this early work, the ability to reflect gross differences
in PDT efficacy has been demonstrated. However, the correlation
is not precise and certainly far from quantitative at present.
Effects of charge on PDT efficacy
Since there is little difference in absorption or photophysical prop-
erties between the three sensitizers (Griffiths et al, 1997), any
differences in PDT effectiveness are likely to be attributable to
differences in uptake and hence sub-tumoural and sub-cellular
distribution. Charge on the sensitizer is likely to play a major role in
this though it is, of course, not possible to carry out a true control
(i.e. same chemical substituent but different charge). PPC was
clearly the most effective sensitizer used in terms of growth delay at
both time intervals and it seems likely that this was due to its
positive charge. Interestingly, however, there was little difference
between the neutral and the negatively charged phthalocyanine. To
date there have been few studies of neutral photosensitizers, in part
because of problems with water-solubility. Similar results were
found for comparison of the same or similar sensitizers in a trans-
planted fibrosarcoma in the rat (Cruse-Sawyer et al, 1998). Both
this study and the recent study referred to above (Cruse-Sawyer et
al, 1998) have suggested that the cationic phthalocyanine is the
most effective in PDT. It was not possible to determine
octanol:water partition coefficients because, for each sensitizer,
almost all of the sensitizer was found in the aqueous layer. The
effects seen here therefore do not appear to be strongly related to
hydrophobicity/hydrophilicity considerations. It therefore seems
likely that the cationic sensitizer is most effective, primarily
because of its positive charge, although as stated earlier, it is not
possible to do a real control and studies with other cationic sensi-
tizers would be necessary to investigate this effect further.
Blood flow measurements
All three sensitizers showed a marked and rapid reduction in blood
flow for the 1-h time interval, as did PPC for the 24-h interval.
This demonstrates that early vascular shutdown occurs during
PDT with all three sensitizers. Moreover, the reduction in blood
flow almost exactly parallels the behaviour of the Pi/total ratio.
The broad correlation drawn between PDT efficacy and the phos-
phate metabolism data therefore applies equally to the relationship
between PDT efficacy and blood flow. The clamping experiments
also appear to demonstrate the importance of vasculature effects to
PDT with this sensitizer, though such experiments are preliminary
and further work is needed for a thorough interpretation of such
data. It is therefore reasonable to assume that vascular shutdown
and consequent hypoxia represents a major part of the mechanism
of growth delay for these sensitizers with this tumour.
General discussion
The present work has clearly demonstrated that there is a relation-
ship between MRS measurements during and immediately
following PDT and the ultimate effect on the tumour and that,
potentially, these measurements may be used to predict that ulti-
mate effect. Clearly, much more work would be necessary before
such predictions could be quantitative. The main clinical value of
such correlation would be the ability it would impart to adjust
treatment parameters at the time of treatment to ensure a
successful outcome, by increasing the PDT effect if the MRS
predictor suggested that treatment would be incomplete. Any
adjustment would be limited to factors which could be manipu-
lated at treatment time (clearly, drug identity and drug dose would
already have been fixed). Such factors could include total light
dose, light dose rate, fractionation of the light dose and possibly
oxygen concentration. Further study in animal tumours using the
sensitizers employed in this work or other sensitizers will be
necessary to evaluate the effects of these parameters.
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